Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: Geron is a biopharmaceutical company focused on developing therapeutic and diagnostic products for oncology and regenerative medicine, as well as research tools for drug discovery. Its core technologies include telomerase, human embryonic stem cells, and nuclear transfer. The company has no products currently on the market and relies on collaborative agreements and equity financings for funding.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2003 |
Six Months Ended June 30, 2002 |
|---|---|---|
| Total Revenues | $547 | $737 |
| Net Loss | $(17,220) | $(19,483) |
| Net Loss Per Share (Basic & Diluted) | $(0.63) | $(0.79) |
| Research & Development Expenses | $14,736 | $18,310 |
| General & Administrative Expenses | $2,508 | $3,049 |
| Cash and Cash Equivalents (Ending) | $10,956 | $28,245 |
| Marketable Securities | $42,330 | $42,383 |
| Total Current Assets | $55,658 | $50,769 |
| Convertible Debentures Outstanding | $0 | $16,316 |
| Accumulated Deficit | $(243,003) | $(225,783) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 26% to $547,000 from $737,000. This was primarily due to the cessation of research support payments from the Kyowa Hakko collaboration, which moved from the research phase to the development phase. This was partially offset by increased license fees and royalties.
- Reduced Net Loss: Net loss improved by approximately 11% to $17.2 million from $19.5 million. The improvement was driven by lower operating expenses resulting from workforce restructurings in June 2002 and January 2003.
- Debt Elimination: All outstanding Series D convertible debentures ($15 million principal) were converted into common stock in May and June 2003. This eliminated the debt liability but resulted in a one-time "Debenture Conversion Expense" of $779,000.
- Capital Raise: The company raised approximately $19.0 million in net proceeds from the sale of 4.4 million shares of common stock in April 2003 and additional proceeds from a license agreement with Transgenomic, Inc. in June 2003.
- Restructuring: In January 2003, the company reduced its workforce by approximately 44% in Menlo Park, recording a restructuring charge of $507,000. In June 2003, a sublease agreement resulted in a recognized liability of approximately $557,000.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates that existing capital resources, interest income, and equipment financing will be sufficient to fund operations through June 30, 2005. However, the company anticipates needing substantial additional capital in the future to continue development.
- Revenue Expectations: The company expects to recognize $259,000 in revenue from existing deferred revenue for the remainder of 2003. Current revenues are not considered predictive of future results.
- Development Progress:
- Oncology: Telomerase inhibitor compounds are in preclinical studies; a Phase 1 clinical trial for a telomerase therapeutic vaccine for metastatic prostate cancer is ongoing with preliminary results showing good tolerability.
- Regenerative Medicine: Animal proof-of-concept testing is underway for hESC-derived neural cells, cardiomyocytes, and pancreatic islet cells.
- Key Risks:
- Regulatory Uncertainty: Significant risks exist regarding FDA approval timelines and the potential for clinical trial failures.
- Capital Needs: Failure to secure additional funding could force the company to delay or eliminate programs.
- Intellectual Property: Ongoing patent interferences regarding nuclear transfer technology with the University of Massachusetts and Infigen Inc. create uncertainty regarding proprietary rights.
- Political/Legal: Ethical and legal debates surrounding human embryonic stem cells and therapeutic cloning could restrict research or funding.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $53.8 million in cash and marketable securities to sustain operations through the projected June 2005 date, considering the high burn rate of R&D.
- Debt Conversion Terms: Review the specific terms of the Series D debenture conversion and the remaining warrants (Series D-2) to assess potential future dilution.
- Patent Interferences: Monitor the status of the patent interferences regarding nuclear transfer technology, as a loss could severely impact the company's core technology platform.
- Collaboration Revenue: Assess the sustainability of revenue streams given the end of the Kyowa Hakko research funding and the reliance on new license agreements.
- Restructuring Liabilities: Confirm the impact of the $557,000 sublease liability and the accretion expense on future cash flows.